RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma
Conditions
- Acoustic Schwannoma
- Adult Anaplastic (Malignant) Meningioma
- Adult Anaplastic Astrocytoma
- Adult Anaplastic Ependymoma
- Adult Brain Stem Glioma
- Adult Choroid Plexus Neoplasm
- Adult Craniopharyngioma
- Adult Diffuse Astrocytoma
- Adult Ependymoblastoma
- Adult Ependymoma
- Adult Giant Cell Glioblastoma
- Adult Glioblastoma
- Adult Gliosarcoma
- Adult Grade I Meningioma
- Adult Grade II Meningioma
- Adult Medulloblastoma
- Adult Mixed Glioma
- Adult Myxopapillary Ependymoma
- Adult Oligodendroglioma
- Adult Papillary Meningioma
- Adult Pilocytic Astrocytoma
- Adult Pineal Gland Astrocytoma
- Adult Pineoblastoma
- Adult Pineocytoma
- Adult Primary Melanocytic Lesion of Meninges
- Adult Subependymal Giant Cell Astrocytoma
- Adult Subependymoma
- Adult Supratentorial Primitive Neuroectodermal Tumor
- Malignant Adult Intracranial Hemangiopericytoma
Interventions
- RADIATION: 3-Dimensional Conformal Radiation Therapy
- DRUG: Gamma-Secretase Inhibitor RO4929097
- RADIATION: Intensity-Modulated Radiation Therapy
- OTHER: Laboratory Biomarker Analysis
- OTHER: Pharmacological Study
- DRUG: Temozolomide
- PROCEDURE: Therapeutic Conventional Surgery
Sponsor
National Cancer Institute (NCI)